The pharmaceutical environment is changing rapidly. The present circumstances bring additional pressures to an already complex and resource constrained situation, leaving the industry to balance great need for new treatments and vaccines with a strong underlying concern over price gouging and lack of demonstrated value for costly new drugs. It’s time for the industry to act on multiple fronts by addressing public concerns and meeting the medical community’s demand for demonstrated value, while at the same time restoring seriously declining return on R&D investments.

 

My recent article in Pharmaceutical Executive addresses these aspects with several calls to action to improve the industry’s development decision process, demonstrate value, elevate the access function and adjust R&D incentive structures to include patients reached and return on investment.